Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CSPC Pharma to Support Drug Discovery Work at Columbia University

publication date: Sep 19, 2014
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) will collaborate with Columbia University of New York City to develop drugs that inhibit aldose reductase, an enzyme that causes eye and nerve damage. Aldose reductase inhibitor drugs may treat a number of serious conditions. CSPC will underwrite research carried out by the Organic Chemistry Collaborative Center at Columbia’s Department of Medicine. CSPC will have the right to develop and commercialize OCCC-discovered molecules, which are initially intended for the China market. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital